Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MRNS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.55
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$29.96M
Einnahmen:
$30.99M
Nettoeinkommen (Verlust:
$-141.41M
KGV:
0.00
EPS:
-2.63
Netto-Cashflow:
$-118.12M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$1.97
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
Firmenname
Marinus Pharmaceuticals Inc
Sektor
Branche
Telefon
484-801-4670
Adresse
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
Vergleichen Sie MRNS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.00 | 29.96M | 30.99M | -141.41M | -118.12M | -2.63 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-08-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-04-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-04-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-01-20 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-09-30 | Eingeleitet | Truist | Buy |
| 2020-07-01 | Eingeleitet | Cowen | Outperform |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-09 | Eingeleitet | Craig Hallum | Buy |
| 2019-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-03-05 | Fortgesetzt | Jefferies | Buy |
| 2019-02-27 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-02-06 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-20 | Eingeleitet | Mizuho | Buy |
| 2018-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-12-14 | Eingeleitet | Laidlaw | Buy |
| 2016-08-10 | Bestätigt | Jefferies | Buy |
| 2016-06-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | Bestätigt | Stifel | Buy |
| 2015-12-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2015-11-17 | Eingeleitet | Jefferies | Buy |
| 2015-10-30 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Marinus Pharmaceuticals Inc Aktie (MRNS) Neueste Nachrichten
Shareholders that Lost Money on Marinus Pharmaceuticals, Inc. (MRNS) Should Contact Levi & Korsinsky About Pending Class ActionMRNS - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com - Defense World
Can The RAISE Study Data Give Marinus' Stock A Boost? - RTTNews
FINAL MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares Sold by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Purchases 354,393 Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Marinus Pharmaceuticals, Inc.(MRNS)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS) - Defense World
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc.(MRNS) Shareholders - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Shareholders - ACCESS Newswire
Kiniksa Pharmaceuticals (NASDAQ:KNSA) versus Marinus Pharmaceuticals (NASDAQ:MRNS) Financial Analysis - Defense World
Fragile X Syndrome Market to Show Remarkable Growth Trends from - openPR.com
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus - MarketScreener
Marinus pharmaceuticals director sells shares for $864 - MSN
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire - The Globe and Mail
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Refractory Status Epilepticus Treatment Market Size in 7MM - openPR.com
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Developmental and Epileptic Encephalopathies Treatment - openPR.com
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com - Armenian Reporter
MRNS LAWSUIT ALERT: Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRNS - ACCESS Newswire
Long-Term Investors in Marinus Pharmaceuticals, Inc. (NASDAQ: - openPR
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for Investors – Contact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Class Action Filed Against Marinus Pharmaceuticals, Inc. (MRNS) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Marinus Pharmaceuticals director sells shares worth $869 - MSN
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock - MSN
Tuberous Sclerosis Complex Therapeutics Market Size Report - openPR
IMMINENT MRNS DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com - Defense World
Marinus Pharmaceuticals (NASDAQ:MRNS) Acquisition Completed by Immedica Pharma AB - Defense World
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stock By Investing.com - Investing.com UK
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals - TipRanks
Marinus Pharmaceuticals, Inc.Common Stock (NQ: MRNS - FinancialContent
Finanzdaten der Marinus Pharmaceuticals Inc-Aktie (MRNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):